Evidence map›Paper›PMID 27335276›Full record

ArticleBlood2016

Time-dependent changes in mortality and transformation risk in MDS.

Michael Pfeilstöcker, Heinz Tuechler, Guillermo Sanz, Julie Schanz, Guillermo Garcia-Manero, Francesc Solé, John M Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus and 24 more

3 registry-linked trialsAbstract readMulticenter Study
In one paragraph

Article in Blood, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 87 papers.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04676945 completednot on this mapstarted 2020, after this paper: background citation

Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients

TypeobservationalSponsorMichael PfeilstöckerRan2020 to 2022Enrolled9,179ConditionsMyelodysplastic Syndromes
NCT05025098 phase2recruitingnot on this mapstarted 2021, after this paper: background citation

Precision Therapy Versus Standard Therapy in Acute Myeloid Leukaemia and Myelodysplastic Syndrome in Elderly

TypeinterventionalSponsorUniversity Hospital, AkershusRan2021 to 2027Enrolled36ConditionsAML, Adult, MDSArmsStandard therapy, Precision therapy
NCT06199557 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 1/2 Multicenter Open-label Study to Investigate Treatment of Hydroxyurea in Combination With Valproic Acid (VPA), or 6- Mercaptopurine in Combination With VPA in Patients With AML or HR-MDS Unfit for Standard Therapy

TypeinterventionalSponsorHaukeland University HospitalRan2024 to 2029Enrolled48ConditionsAcute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, AdultArmsHydroxyurea, Hydroxycarbamide, Valproic acid, 6-Mercaptopurine (6-MP)
3 · Its place in the literature

Who cites it

87 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Therapy of high-risk myelodysplastic syndromes.Bone marrow transplantation · 2026
    Review
  6. Article
  7. Article
  8. Updates in low/intermediate-risk MDS.Hematology. American Society of Hematology. Education Program · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.Current treatment options in oncology · 2024
    Review
  19. Review
  20. Role of reactive oxygen species in myelodysplastic syndromes.Cellular & molecular biology letters · 2024
    Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors.

Michael PfeilstöckerHanusch Hospital and L. Boltzmann Cluster Oncology, Vienna, Austria;
Heinz TuechlerL. Boltzmann Institute for Leukemia Research, Vienna, Austria;
Guillermo SanzHospital Universitario La Fe, Valencia, Spain;
Julie SchanzGeorg August Universität, Göttingen, Germany;
Guillermo Garcia-ManeroThe University of Texas MD Anderson Cancer Center, Houston, TX;
Francesc SoléInstitut de Recerca contra la Leucèmia Josep Carreras, Barcelona, Spain;
John M BennettJames P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY;
David BowenSt James's University Hospital, Leeds, United Kingdom;
Pierre FenauxHopital Avicenne, Assistance Publique-Hopitaux de Paris (AP-HP)/University of Paris XIII, Bobigny, France;
Francois DreyfusHopital Cochin, AP-HP, University of Paris V, Paris, France;
Hagop KantarjianThe University of Texas MD Anderson Cancer Center, Houston, TX;
Andrea KuendgenHeinrich-Heine University Hospital, Düsseldorf, Germany;
Luca MalcovatiFondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy;
Mario CazzolaFondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy;
Jaroslav CermakInstitute of Hematology and Blood Transfusion, Praha, Czech Republic;
Christa FonatschMedical University of Vienna, Vienna, Austria;
Michelle M Le BeauUniversity of Chicago Comprehensive Cancer Research Center, Chicago, IL;
Marilyn L SlovakDepartment of Pathology, University of New Mexico, Albuquerque, NM;
Alessandro LevisAntonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy;
Michael LuebbertUniversity of Freiburg Medical Center, Freiburg, Germany;
Jaroslaw MaciejewskiCleveland Clinic, Cleveland, OH;
Sigrid Machherndl-SpandlElisabethinen Hospital, Linz, Austria;
Silvia M M MagalhaesFederal University of Ceara, Fortaleza, Brazil;
Yasushi MiyazakiNagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
Mikkael A SekeresCleveland Clinic, Cleveland, OH;
Wolfgang R SperrDivision of Hematology, Medical University of Vienna, Vienna, Austria;
Reinhard StauderUniversity Hospital of Innsbruck, Innsbruck, Austria;
Sudhir TauroUniversity of Dundee, Dundee, United Kingdom;
Peter ValentDivision of Hematology, Medical University of Vienna and L. Boltzmann Cluster Oncology, Vienna, Austria;
Teresa VallespiHospital Universitario Vall d'Hebron, Barcelona, Spain;
Arjan A van de LoosdrechtVrije Universiteit Medical Center, Amsterdam, The Netherlands; and.
Ulrich GermingHeinrich-Heine University Hospital, Düsseldorf, Germany;
Detlef HaaseGeorg August Universität, Göttingen, Germany;
Peter L GreenbergStanford Cancer Institute, Stanford, CA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.

Indexed as

AgedCell Transformation, NeoplasticFemaleHumansKaplan-Meier EstimateMaleMyelodysplastic SyndromesRisk FactorsTime FactorsWorld Health Organization

Identifiers

PMID27335276
PMCPMC5161006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.